AG23042

AG23042 is an investigational oral drug developed by Ahn-Gook Pharmaceutical, being studied primarily in combination with AG23041 as part of the fixed-dose combination AG2304 for the treatment of hypercholesterolemia. The individual mechanism of action, molecular target, and chemical identity of AG23042 are not explicitly disclosed in public sources—it is likely a new molecular entity intended as a component of combination therapy to lower blood lipid levels[1][3]. AG23042, along with AG23041, is administered to healthy volunteers in pharmacokinetic trials comparing the single-entity agents to the AG2304 combination product; these studies aim to establish bioequivalence, safety, and pharmacokinetic profiles[1][3][7]. Its primary intended indication is the management of elevated cholesterol, but further details on its molecular modality or mechanism remain unavailable.

Brand names

AG23042AG-23042AG 23042

Other names

AG23042AG-23042AG 23042